恩替卡韦联合扶正化瘀胶囊治疗乙型肝炎肝硬化的疗效分析

打开文本图片集

【摘要】目的：探討恩替卡韦联合扶正化瘀胶囊治疗乙型肝炎肝硬化的疗效。方法：选取2020年1月—2022年12月院内收治的88例乙型肝炎肝硬化患者，随机分为两组。对照组采取恩替卡韦治疗，观察组采取恩替卡韦联合扶正化瘀胶囊治疗。比较两组治疗效果。结果：观察组的谷草转氨酶复常率和乙肝病毒转阴率明显高于对照组（P0.05）；治疗后，两组的CⅣ、AST、PCⅢ、ALT、LN、TBil和HA水平均明显降低，且观察组CⅣ、AST、PCⅢ、ALT、LN、TBil和HA水平均低于对照组（P

【关键词】恩替卡韦；扶正化瘀胶囊；乙型肝炎肝硬化

Analysis of curative effect of entecavir combined with Fuzheng Huayu capsule in the treatment of hepatitis B cirrhosis

FENG Weiwei

Department of Internal Medicine， Kaole Township Health Center of Dongxiang County， Linxia， Gansu， Linxia， Gansu 731400， China

【Abstract】Objective：To investigate the effect of entecavir combined with Fuzheng Huayu capsule in the treatment of hepatitis B cirrhosis.Methods：A total of 88 patients with hepatitis B cirrhosis admitted to the hospital from January 2020 to December 2022 were selected and randomly divided into two groups.The control group was treated with entecavir and the observation group was treated with Fuzheng Huayu capsule.The therapeutic effects between the two groups were compared.Results：The normalization rate of glutamic oxalacetic transaminase and the negative conversion rate of hepatitis B virus in the observation group were significantly higher than those in the control group （P0.05）；After treatment，the levels of CⅣ，AST，PCⅢ，ALT，LN，TBil and HA in both groups were significantly decreased，and the levels of CⅣ，AST，PCⅢ，ALT，LN，TBil and HA in the observation group were significantly lower than those in the control group （P

【Key Words】Entecavir； Fuzheng Huayu capsule； Hepatitis B cirrhosis

乙型肝炎病毒常常会侵犯和损伤机体内的肝细胞，从而造成大量肝细胞坏死，导致肝脏的结缔组织发生增生，造成肝纤维化现象，若长期处于肝纤维化状态，会增加肝硬化发生的概率[1-2]。（剩余3769字）